Scotiabank Keeps Their Buy Rating on Blueprint Medicines (BPMC)

Scotiabank analyst Louise Chen maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $150.00. The company’s shares closed yesterday at $99.25.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Chen covers the Healthcare sector, focusing on stocks such as Zai Lab, Sarepta Therapeutics, and Palvella Therapeutics. According to TipRanks, Chen has an average return of -9.6% and a 39.51% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Blueprint Medicines with a $130.19 average price target, implying a 31.17% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $135.00 price target.

BPMC market cap is currently $6.41B and has a P/E ratio of -92.61.

Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.